TriLink BioTechnologies
Manufactures modified nucleic acids and mRNA reagents for biotechnology.
Company facts
- Founded
- 1996
- Employees
- 570
- Headquarters
- United States
- Type
- Public
- Listed
- NASDAQ: MRVI
About
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) specializing in the synthesis of nucleic acids, NTPs, and mRNA capping analogs. With over 25 years of experience, TriLink has established itself as a pioneering leader in nucleic acid synthesis and manufacturing, supporting therapeutic, vaccine, and diagnostic innovations for companies worldwide. TriLink’s proprietary CleanCap® technology offers an efficient mRNA co-transcriptional capping method that streamlines manufacturing by eliminating extra enzymatic steps, resulting in improved capping efficiency and higher yields compared to traditional methods. The organization caters to biopharma companies transitioning from research to clinical trials, providing a wide range of manufacturing-grade products, from research use only (RUO) to full Good Manufacturing Practice (GMP) grade, with available scale-up and technology transfer capabilities.